In a woman with a prior spontaneous preterm birth of unknown cause, what progesterone therapy is indicated and what regimen should be used?

Progesterone Therapy for Prior Spontaneous Preterm Birth

For a woman with a singleton pregnancy and prior spontaneous preterm birth of unknown cause, initiate 17-alpha-hydroxyprogesterone caproate (17P) 250 mg intramuscularly weekly starting at 16-20 weeks and continuing until 36 weeks of gestation. 1

Primary Recommendation

The Society for Maternal-Fetal Medicine (SMFM) guideline clearly establishes that 17P is the recommended progestogen for women with singleton gestations and prior spontaneous preterm birth between 20-36 6/7 weeks. 1 This recommendation is based on evidence showing reduction in recurrent preterm birth and improved neonatal outcomes.

Specific Regimen:

• Agent: 17-alpha-hydroxyprogesterone caproate (17P)
• Dose: 250 mg intramuscularly
• Frequency: Weekly
• Start: 16-20 weeks of gestation (preferably at 16 weeks)
• Continue: Until 36 weeks of gestation or delivery

Important Clinical Algorithm

If Cervical Shortening Develops on 17P:

Continue 17P therapy even if the cervix shortens to ≤25 mm on transvaginal ultrasound at <24 weeks. 1 The guideline explicitly states there is insufficient evidence to switch to vaginal progesterone in this scenario, and it is reasonable to continue 17P. 1

• If cervical length shortens to <25 mm at <24 weeks: Consider adding cervical cerclage while continuing 17P 1
• If cervical length is <15 mm: Cerclage may be more beneficial than progesterone alone 1

Critical Distinction: Vaginal Progesterone is NOT a Substitute

The 2017 SMFM statement specifically reaffirms that vaginal progesterone should NOT be considered a substitute for 17P in women with prior spontaneous preterm birth. 2 This is a crucial point because:

• Vaginal progesterone has not been adequately proven to decrease recurrent preterm birth in women with prior spontaneous preterm birth in multiple RCTs 2
• The evidence for 17P in this population is stronger and more consistent
• Vaginal progesterone is reserved for a different population: women without prior preterm birth but with a sonographically short cervix (≤20 mm) detected at around 24 weeks 1

Evidence Strength and Nuances

The guideline evidence from 2012 and reaffirmed in 2017 1, 2 prioritizes 17P based on:

• Demonstrated reduction in perinatal mortality (RR 0.50) 3
• Reduction in preterm birth <34 weeks (average RR 0.31) 3
• Reduction in neonatal death (RR 0.45) 3
• Reduction in NICU admission (RR 0.24) 3

Common Pitfall to Avoid:

Do not switch from 17P to vaginal progesterone if cervical shortening occurs. The evidence does not support this practice, and the guideline recommends continuing 17P throughout pregnancy despite cervical changes. 1, 2 If intervention is needed for a very short cervix, add cerclage rather than changing progesterone formulation.

What Vaginal Progesterone Does NOT Do in This Population

Vaginal progesterone is not indicated for:

• Women with prior spontaneous preterm birth as primary prevention (this is 17P's indication) 1, 2
• Multiple gestations 1
• Active preterm labor 1
• Preterm premature rupture of membranes 1

Vaginal progesterone (90 mg gel or 200 mg suppository daily) is specifically for women without prior preterm birth who are found to have a cervical length ≤20 mm at around 24 weeks on screening ultrasound. 1

Practical Implementation

Start 17P as soon as the pregnancy is confirmed viable in the second trimester, ideally between 16-20 weeks. Weekly intramuscular injections require patient counseling about:

• Injection site reactions (common)
• Need for consistent weekly administration
• Continuation until 36 weeks regardless of cervical length changes

If the patient was already receiving 17P for prior preterm birth and membranes rupture prematurely, continue 17P as there is no evidence to discontinue it. 1